CG Labz
Peptide Library / Recovery / Inflammation

KPV

α-MSH C-terminal tripeptide (Lys-Pro-Val)

KPV Research Protocol

Complete Research Guide 4 min read2 peer-reviewed references

Quickstart Overview

KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH and carries that hormone's anti-inflammatory activity in a small, stable fragment. It is studied in inflammatory bowel disease, dermal inflammation and mast-cell modulation, and works orally and topically as well as by injection.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Literature Range
200–500 mcg per administration
Measuring Reference
At 5 mg/mL: 500 mcg = 0.1 mL = 10 units
Frequency
1–2× daily
Route (studies)
SC, oral or topical
Cycle
4–8 weeks

Scientific Data

Molecular Formula
—
Molecular Weight
358.43 Da
Sequence
Lys-Pro-Val
Sequence Length
9
CAS
Research compound
Peptide Family
Tripeptide
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.100 mL
Syringe Units
10.0 U
Doses / Vial
20

Units assume a U-100 insulin syringe (100 units = 1 mL). Works orally (PepT1 uptake) and topically as well as subcutaneously.

Frequency: 1–2× daily

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 8-week protocol at approximately 500 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 500 mcg/day × 56 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model NF-κB anti-inflammatory activity in gut and skin.
Schedule
Daily, 4–8 weeks.
Dose Range
200–500 mcg per dose.

Dosing Protocol

Standard
200–500 mcg once or twice daily
Frequency
1–2× daily
Oral
Absorbed via PepT1 — used in gut protocols
Cycle Length
4–8 weeks
Timing
Empty stomach for GI models
Route
Subcutaneous or oral

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Among the best-tolerated compounds in the catalog.
  • Anti-inflammatory rather than regenerative — often paired with BPC-157 for repair.

How This Works

KPV inhibits NF-κB activation and reduces pro-inflammatory cytokines (IL-6, IL-8, TNF-α) in epithelial and immune cells, largely independent of melanocortin-receptor signalling. In the gut it is transported into colonic cells via the PepT1 transporter, where it dampens inflammation — the basis of its efficacy in colitis models. It also stabilises mast cells and shows antimicrobial activity.

Potential Benefits & Side Effects

Reported in research
  • Potent NF-κB-mediated anti-inflammatory activity
  • Reduced colitis severity in animal models
  • Mast-cell stabilisation and dermal anti-inflammatory effects
  • Oral and topical activity (PepT1 uptake)
  • Antimicrobial effects reported
Possible considerations
  • Very well tolerated in preclinical models
  • Mild injection-site irritation
  • Limited human clinical data
  • Effects are anti-inflammatory, not regenerative

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Gastroenterology
    Dalmasso G. et al. PepT1-mediated KPV uptake reduces intestinal inflammation.
    View Source
  2. [2] Journal of Immunology
    Brzoska T. et al. α-MSH-derived tripeptides: anti-inflammatory effects.
    View Source